Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Histone deacetylases (HDACs) are key regulators of gene expression and are validated anticancer targets.
• Approved histone deacetylase inhibitors (HDACis) demonstrate efficacy, but resistance and synergistic effects necessitate novel therapeutic strategies.
• Bifunctional agents, such as hybrid inhibitors, can simultaneously target multiple pathways for enhanced therapeutic outcomes.

Purpose of the Study:

• To review and summarize the landscape of reported kinase/HDAC hybrid inhibitors.
• To highlight the potential of these bifunctional agents in anticancer drug discovery.
• To provide a perspective on the development of novel therapeutic strategies targeting cancer.

Main Methods:

• Literature review of scientific databases.
• Analysis of reported kinase/HDAC hybrid inhibitor structures and activities.
• Synthesis of findings on the therapeutic potential of these hybrid molecules.

Main Results:

• Numerous kinase/HDAC hybrid inhibitors have been designed and synthesized.
• These hybrid molecules demonstrate the potential for simultaneous inhibition of kinase and HDAC targets.
• The development of bifunctional agents represents a promising avenue for overcoming drug resistance and enhancing synergistic effects in cancer treatment.

Conclusions:

• Kinase/HDAC hybrid inhibitors represent a promising class of anticancer agents.
• Simultaneous targeting of kinases and HDACs offers a strategic advantage over single-target inhibitors.
• Further research and development in this area hold significant potential for advancing cancer therapy.